In a lab in Suzhou, a cell that usually patrols the body's borders is being handed a new set of instructions. The instruction: go find a solid tumor, and do the thing CAR-T never could.
The quiet specialists
Cure Genetics does not look like a company in a hurry. Thirteen to a couple hundred people, depending on who is counting, tucked into Suzhou's Biomedical Industrial Park alongside several hundred other biotechs that all smell faintly of liquid nitrogen. No consumer app. No glossy keynote. Just two platforms, a handful of clinical programs, and a mission statement so plain it is almost a relief: improving lives through cell and gene therapy.
What sets them apart is the cell they bet on. While most of the industry stampeded toward CAR-T, Cure Genetics picked a stranger collaborator - the invariant natural killer T cell, a hybrid that sits between innate and adaptive immunity. It is the immunological equivalent of hiring the person nobody else interviewed. And in 2026, with interim data presented at ASGCT and big-pharma partners on the books, the bet is starting to look less eccentric and more deliberate.
Most CAR-T works in blood cancers. Solid tumors hide. Cure Genetics built its whole thesis around the cells that are good at finding things.
- The Cure Genetics thesis, compressedThe tumors that don't answer the door
Here is the awkward truth the cell-therapy revolution doesn't print on its banners: it mostly works on blood. Engineered T cells have rewritten the odds for leukemias and lymphomas. Aim them at a solid tumor - kidney, liver, lung - and they stall at the gate. The tumor builds a hostile neighborhood, the cells can't infiltrate, and the therapy that cured one patient does nothing for the next.
Gene therapy has a mirror-image problem. Adeno-associated virus is a beautiful delivery truck, but it does not know your address. Getting an AAV vector to the brain, the heart, or the kidney - and only there - is a problem the field has wrestled with for two decades. Wrong tissue, wasted dose, unwanted immune attention.
Two hard problems, both about reaching a place the body would rather you didn't. Cure Genetics decided that was the whole job.
An AAV vector is a delivery truck with no address. VELP is the company's attempt to teach it the way.
- On the gene therapy half of the houseYuanyuan Xu and the unfashionable cell
Cure Genetics was founded in 2016 by Yuanyuan Xu, who still serves as chairman and CEO. The founding bet was contrarian in the most expensive way a biotech bet can be: pick a cell type the rest of the field had filed under "interesting, someday." The invariant NKT cell is rare, finicky, and - critically - good at slipping into tissue and stirring up the local immune environment. Exactly the trick solid tumors are built to prevent.
The second half of the bet was to not specialize too narrowly. Rather than become a one-trick cell shop, the company built a parallel gene therapy platform around directed evolution of AAV vectors. Two platforms under one roof is harder to fund and harder to explain. It is also a hedge: if the immune system is the lock, you may as well work on more than one key.
The whole company in four numbers, which is unfair to roughly forty other numbers that also matter. Funding figures vary by source; we used the most consistently reported.
Two platforms, one stubborn goal
The company's work splits cleanly into the cells and the vectors.
AIMS · CAR-NKT
CELL THERAPYInvariant natural killer T cells, engineered with chimeric antigen receptors and pointed at solid tumors. The selling point isn't novelty for its own sake - it's infiltration. NKT cells get into the tumor microenvironment and reshape it, which is precisely where conventional CAR-T runs out of road.
VELP™ · AAV
GENE THERAPYA directed-evolution platform that builds large viral libraries and screens them in vivo, letting selection surface the AAV variants that actually reach the nervous system, heart, or kidney. Less design-by-committee, more survival of the fittest capsid.
Out of those platforms come the named programs. CGC729, an anti-CD70 CAR-NKT therapy, is in Phase I for relapsed and refractory metastatic renal cell carcinoma. CGC-602, a PD-1-IL-2v bispecific antibody, rounds out the immuno-oncology side. The pipeline is small. It is also pointed at problems that have humbled much larger companies.
A decade, abbreviated
What's on the record
Conviction is cheap in biotech. Data is not. Cure Genetics' strongest public signal came at the 27th ASGCT Annual Meeting, where it presented interim Phase I results for its CAR-NKT program in renal cell carcinoma in an oral presentation - the kind of slot a conference reserves for work the field wants to scrutinize. The reported emphasis: a favorable safety profile in a patient population with few good options.
Then there are the partners. Boehringer Ingelheim, a top-twenty global pharma, signed on for AAV vector development. Frametact Limited collaborated on gene therapy for neurological disease. Partners of that caliber do diligence; their presence is a third party betting alongside the founders.
And the team itself is evidence. The 2023 hiring run pulled in Dr. Ren Li - who previously handled technology transfer for Juno's cell therapy products at Bristol-Myers Squibb - as Cell Therapy CTO. People with that resume do not usually join companies they expect to fizzle.
Where the money landed
Bars scaled to total raised. Revenue is an external estimate - clinical-stage biotech runs on capital, not sales. The gap between the orange bar and the teal one is, essentially, the bet.
A clinical-stage balance sheet, drawn honestly: most of the money is going in, and the payoff is still in a freezer somewhere being assayed.
Partners of Boehringer Ingelheim's size do not sign casually. Their diligence is a second opinion you didn't have to pay for.
- On why partnerships count as proofImproving lives, stated plainly
The mission line - "improving lives through cell and gene therapy" - is refreshingly free of adjectives. No "revolutionary," no "paradigm." That restraint is a tell. The company is aiming at diseases where the bar is brutal and honest: relapsed renal cancer, genetic disorders of the brain and kidney, the conditions where patients have run out of standard options and the word "transformative" has to be earned in a trial, not a press release.
It helps that the two platforms point the same direction. Both are, at heart, about precision delivery to a place the body guards. Reach the tumor. Reach the right tissue. Do it without collateral damage. That is the unglamorous center of the entire enterprise.
If the unfashionable cell works
Solid tumors are most of cancer. A cell therapy that genuinely infiltrates them would not be a niche win - it would be a category. Tissue-specific AAV delivery would unlock gene therapies for organs the field has struggled to address safely. Neither is guaranteed. Phase I is a long way from a label, and biotech graveyards are full of elegant theses.
But back in that Suzhou lab, the natural killer T cell now has its new instructions and a clinical readout behind it. The border-patrol cell has a tumor to find. Whether it succeeds is still being measured, one renal cancer patient at a time - which is exactly how a serious answer to a hard problem is supposed to look. Not loud. Just enrolled.
No official channel was confirmed at publication - these are open searches, not endorsements. If they launch one, it'll go here.